Literature DB >> 6263686

Vasoactive intestinal peptide (VIP) control of glycogenolysis in the human colon carcinoma cell line HT-29 in culture.

M Rousset, M Laburthe, G Chevalier, C Boissard, G Rosselin, A Zweibaum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6263686     DOI： 10.1016/0014-5793(81)81027-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


× No keyword cloud information.
  7 in total

1.  Hormonal control of fructose 2,6-bisphosphate concentration in the HT29 human colon adenocarcinoma cell line. Alpha 2-adrenergic agonists counteract effect of vasoactive intestinal peptide.

Authors:  C Denis; H Paris; J C Murat
Journal:  Biochem J       Date:  1986-11-01       Impact factor: 3.857

2.  Storage of glycogen in rat colonic epithelium during induction of secretion and absorption in vitro.

Authors:  P Mestres; M Diener; W Rummel
Journal:  Cell Tissue Res       Date:  1990-07       Impact factor: 5.249

3.  Insulin controls key steps of carbohydrate metabolism in cultured HT29 colon cancer cells.

Authors:  T Babia; C Denis-Pouxviel; J C Murat; A M Gomez-Foix; V Trocheris; J J Guinovart; F Bosch
Journal:  Biochem J       Date:  1989-07-01       Impact factor: 3.857

4.  Agonist-induced glycogenolysis in rabbit retinal slices and cultures.

Authors:  H Ghazi; N N Osborne
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

5.  Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.

Authors:  A Couvineau; M Rousset; M Laburthe
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857

6.  Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine.

Authors:  Dulari Jayawardena; Grace Guzman; Ravinder K Gill; Waddah A Alrefai; Hayat Onyuksel; Pradeep K Dudeja
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-04-06       Impact factor: 4.052

7.  Anti-cell surface monoclonal antibodies which antagonize the action of VIP in a human adenocarcinoma cell line (HT 29 cells).

Authors:  J Pichon; M Hirn; J M Muller; P Mangeat; J Marvaldi
Journal:  EMBO J       Date:  1983       Impact factor: 11.598
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.